Table 3 |
|||
| Antioxidant enzyme activity and lipid peroxidation before and after intervention | |||
| Placebo (n = 19) | Low-dose (n = 19) | High-dose (n = 19) | |
| SOD activity (U/ml) | |||
| Pre-treatment | 12.6±0.97 | 10.1±0.68 | 11.9±0.98 |
| Post-treatment | 12.2±0.96 | 12.1±1.03* | 14.2±1.15* |
| Change | −0.46±0.57 | 1.95±0.80 | 2.24±0.86† |
| GPx activity (nmol/min/ml) | |||
| Pre-treatment | 41.1±3.71 | 34.3±1.88 | 34.9±2.53 |
| Post-treatment | 39.1±3.72 | 37.4±2.27 | 43.5±2.53** |
| Change | −2.00±2.08 | 3.05±2.15 | 8.66±2.63† |
| Catalase (nmol/min/ml) | |||
| Pre-treatment | 103.2±11.5 | 94.5±8.56 | 86.9±11.7 |
| Post-treatment | 99.0±13.2 | 118.3±11.8 | 135.5±12.3** |
| Change | −4.17±12.4 | 23.8±12.4 | 48.5±12.3† |
| 8-epi-PGF2α (pg/mg creatinine)a) | |||
| Pre-treatment | 1450.3±103.7 | 1519.0±222.3 | 1516.3±105.9 |
| Post-treatment | 1641.6±136.5 | 1323.4±106.6 | 1383.5±120.2 |
| Change | 191.3±107.7 | −195.6±147.6† | −132.8±127.9† |
SOD, superoxide dismutase; GPx, glutathione peroxidase; 8-epi-PGF2α, 8-epi-prostaglandin F2α.
a)Tested after logarithmic transformation.
Results are expressed as standard error of the mean (SEM).
Tested by Wilcoxon signed-rank test or analysis of covariance (ANCOVA) using a general linear model (GLM) with adjustments for age, sex, BMI, smoking, drinking, systolic BP, diastolic BP, and baseline values.
*P <0.05,**P <0.01 compared with the baseline in each group; †P <0.05, ††P <0.01 compared with the placebo group.
Kim et al. Nutrition Journal 2012 11:47 doi:10.1186/1475-2891-11-47
